Brown Advisory’s Sage Therapeutics SAGE Stock Holding History

Brown Advisory’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-7,288	Closed	-$1.16M	–	1231
2019 Q1	$1.16M	Buy	7,288 +2,562	+54%	+$371K	﹤0.01%	775
2018 Q4	$453K	Buy	4,726 +1,726	+58%	+$198K	﹤0.01%	957
2018 Q3	$424K	Hold	3,000	–	–	﹤0.01%	1046
2018 Q2	$470K	Sell	3,000 -126	-4%	-$19.8K	﹤0.01%	989
2018 Q1	$503K	Sell	3,126 -14	-0.4%	-$2.38K	﹤0.01%	837
2017 Q4	$517K	Buy	+3,140	New	+$304K	﹤0.01%	867
2017 Q3	–	Sell	-3,111	Closed	-$248K	–	1222
2017 Q2	$248K	Sell	3,111 -89	-3%	-$6.43K	﹤0.01%	1074
2017 Q1	$227K	Buy	+3,200	New	+$187K	﹤0.01%	1070

Other funds holding SAGE

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Brown Advisory's SAGE Position: Q2 2019 in Review

Brown Advisory sold out of Sage Therapeutics (SAGE) in Q2 2019, closing a stake of 7,288 shares — an estimated $1.16M sold.

Brown Advisory first reported a position in SAGE in Q1 2017 and held it in 8 quarters. The position peaked at $1.16M in Q1 2019. 272 funds tracked by Wall St. Rank hold SAGE as of Q2 2019.

Brown Advisory reported no remaining Sage Therapeutics position as of Q2 2019 after selling out during the quarter.
Brown Advisory sold 7,288 Sage Therapeutics shares in Q2 2019, an estimated $1.16M.
Brown Advisory first reported a position in Sage Therapeutics in Q1 2017 and held it in 8 quarters.
Brown Advisory's Sage Therapeutics position peaked at $1.16M in Q1 2019.
272 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2019.

Based on Brown Advisory's 13F filing for Q2 2019, filed 12 Aug 2019.